Search for: "Pfizer, Inc. v. Miles, Inc."
Results 1 - 15
of 15
Sorted by Relevance
|
Sort by Date
18 Jul 2014, 11:55 am
Pfizer, Inc., 716 F.3d 1087, 1092-93 (8th Cir. 2013). [read post]
20 Mar 2009, 2:05 am
Crews, 955 A.2d 769, 781 (Md. 2008); Miles Laboratories, Inc. v. [read post]
5 Jul 2007, 10:37 am
Miles Laboratories, Inc., 802 P.2d 1346, 1353 (Wash. 1991); McKee v. [read post]
24 Sep 2009, 5:09 am
Miles Laboratories, Inc., 810 F. [read post]
28 Sep 2009, 1:31 am
Miles Laboratories, Inc., 810 F. [read post]
28 Sep 2009, 1:31 am
Miles Laboratories, Inc., 810 F. [read post]
28 Sep 2009, 1:31 am
Miles Laboratories, Inc., 810 F. [read post]
8 Nov 2013, 5:00 am
Pfizer, Inc., 2013 N.Y. [read post]
2 Jun 2011, 12:46 pm
Pfizer, Inc., 153 S.W.3d 758, 761 (Ky. 2004) (dictum also extends rule to medical devices). [read post]
15 Sep 2009, 10:54 pm
See Miles Labs., Inc. v. [read post]
28 Apr 2011, 3:18 pm
Brown v. [read post]
22 Feb 2008, 1:30 pm
The decision in Reidel v. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz… [read post]
